Developing The Next Big Thing
Med Tech Gurus
00:00
The Future of SFA Therapeutics
SFA's platform enables us to modify cytokine levels for specific diseases. We're in phase one B in a 30 patient trial in psoriasis. In a month or so, we're starting a trial with a second IND aimed at treating patients with fibrosis and NASH. It's based on the original drug that Mark Feidlson discovered plus a lot of translational science work that Allah Arzummanian has done.
Play episode from 33:51
Transcript
